Rita Nanda
University of Chicago · University of Chicago Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rita Nanda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:49 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07553234 · Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer TreatmentUniversity of Chicago · recruiting · Breast Cancer · principal investigator
- Ph2NCT03225547 · Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast CancerUniversity of Chicago · terminated · Triple Negative Breast Neoplasms, Breast Cancer · principal investigator
- Ph2NCT02788981 · Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast CancerUniversity of Chicago · active not recruiting · Breast Cancer · principal investigator
- N/ANCT02637375 · A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerUniversity of Chicago · withdrawn · Breast Cancer · principal investigator
- Ph1NCT02046421 · Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerUniversity of Chicago · completed · Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer · principal investigator
- Ph1NCT02014337 · Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsCorcept Therapeutics · completed · Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma · principal investigator
- Ph1NCT01493310 · Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast CancerUniversity of Chicago · completed · Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer · principal investigator
- Ph2NCT00517361 · Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast CancerUniversity of Chicago · terminated · Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- UChicago Interdisciplinary Cancer Health Disparities SPOREP20CA233307 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2018 to 2020 · $1,075,670 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Clinical and Experimental TherapeuticsP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI Wendy Stock · fiscal years 2010 to 2026Named on NCT02046421
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:49 UTC. The ranking covers the 200 most relevant of 79 PubMed records, and a shared surname and initials can bring in a namesake. All 79 on PubMed
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.J Clin Oncol · 20161,253 citationsRCR 38.8
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Ann Oncol · 2019696 citationsRCR 24.2
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.JAMA Oncol · 2019654 citationsRCR 23.2
- 620 citationsRCR 24.3
- 548 citationsRCR 19.1
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med · 2016456 citationsRCR 12.7
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.J Clin Oncol · 2020417 citationsRCR 15.8
- Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.J Clin Oncol · 2018413 citationsRCR 14.1
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell · 2021307 citationsRCR 13.7
- Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med · 2016296 citationsRCR 7.8